Showing results (1-10 of 42) with videos related to

Sort By:
Pageof 5
Expert Opinion on Drug Safety|March 30, 2005
The development and application of imatinibRobin L Jones, Ian R Judson
The Lancet. Oncology|December 17, 2008
Eligibility of patients with brain metastases for phase I trials: time for a rethink?Craig P Carden, Roshan Agarwal, Frank Saran, et al.
European Journal of Cancer (Oxford, England : 1990)|November 18, 2005
Differential sensitivity of liposarcoma subtypes to chemotherapyRobin L Jones, Cyril Fisher, Omar Al-Muderis, et al.
Cancer Journal (Sudbury, Mass.)|June 8, 2010
Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedsideDavid Olmos, Daniel S W Tan, Robin L Jones, et al.
Sarcoma|June 4, 2008
A Case of Ovarian Fibromatosis and Massive Ovarian Oedema Associated With Intra-Abdominal Fibromatosis, Sclerosing Peritonitis and Meig's SyndromeEmma L Spurrell, Yen C Yeo, Terence P Rollason, et al.
Nature Reviews. Clinical Oncology|March 20, 2014
Systemic treatment of soft-tissue sarcoma-gold standard and novel therapiesMark Linch, Aisha B Miah, Khin Thway, et al.
The Lancet. Oncology|March 9, 2017
Soft tissue sarcomas in adolescents and young adults: a comparison with their paediatric and adult counterpartsWinette T A van der Graaf, Daniel Orbach, Ian R Judson, et al.
Sarcoma|June 8, 2011
Targeting the Insulin-Like Growth Factor 1 Receptor in Ewing's Sarcoma: Reality and ExpectationsDavid Olmos, Ana Sofia Martins, Robin L Jones, et al.
American Journal of Clinical Oncology|March 23, 2011
Role of palliative chemotherapy in advanced epithelioid sarcomaRobin L Jones, Anastasia Constantinidou, David Olmos, et al.
Sarcoma|May 29, 2010
Clinical benefit of second-line palliative chemotherapy in advanced soft-tissue sarcomaAnna Minchom, Robin L Jones, Cyril Fisher, et al.
Pageof 5